We are live on
!
Find out more
NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.23B
1-Year Est. Return
81.32%
This Fund
S&P 500
This Quarter
Est. Return
-1.97%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$2.1B
AUM Growth
+$66.6M
(+3.3%)
Cap. Flow
-$64.5M
Cap. Flow
% of AUM
-3.07%
Top 10 Holdings %
Top 10 Hldgs %
64.85%
Holding
56
New
2
Increased
9
Reduced
13
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cable One
CABO
|
+$43.9M |
| 2 |
Corcept Therapeutics
CORT
|
+$21.4M |
| 3 |
Salesforce
CRM
|
+$17M |
| 4 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$12.2M |
| 5 |
ASML
ASML
|
+$5.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boston Scientific
BSX
|
+$70M |
| 2 |
Brookfield
BN
|
+$19.8M |
| 3 |
Nkarta
NKTX
|
+$19.4M |
| 4 |
ACLX
Arcellx
ACLX
|
+$15.8M |
| 5 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
+$12.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 51.95% |
| 2 | Technology | 13.97% |
| 3 | Financials | 4.89% |
| 4 | Communication Services | 3.25% |
| 5 | Consumer Discretionary | 1.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Vanguard Morningstar Total Stock Market ETF
VTI
$646B
| $501M | 23.88% |
1,525,550
| – | – |
|
2
Stryker
SYK
$135B
| $161M | 7.7% |
796,941
| – | – |
|
|
CTLT
3
DELISTED
CATALENT, INC.
CTLT
| $118M | 5.63% |
1,632,878
| – | – |
|
|
4
Brookfield
BN
$102B
| $103M | 4.89% |
4,655,134
-765,099
| -14% | -$19.8M |
|
|
5
ASML
ASML
$596B
| $94.2M | 4.49% |
226,770
+11,770
| +5% | +$5.9M |
|
|
6
Corcept Therapeutics
CORT
$9.98B
| $85.3M | 4.07% |
3,327,768
+801,278
| +32% | +$21.4M |
|
|
7
Salesforce
CRM
$154B
| $83.2M | 3.97% |
578,500
+100,000
| +21% | +$17M |
|
8
Steris
STE
$22.9B
| $77.8M | 3.71% |
467,687
| – | – |
|
|
9
Boston Scientific
BSX
$68.4B
| $68.3M | 3.26% |
1,762,942
-1,745,846
| -50% | -$70M |
|
|
10
Cable One
CABO
$237M
| $68.3M | 3.25% |
80,023
+35,550
| +80% | +$43.9M |
|
11
Apple
AAPL
$4.97T
| $63.8M | 3.04% |
461,379
| – | – |
|
|
ACLX
12
DELISTED
Arcellx
ACLX
| $59.9M | 2.86% |
3,191,878
-825,000
| -21% | -$15.8M |
|
13
Edgewise Therapeutics
EWTX
$4.28B
| $59.7M | 2.85% |
6,071,703
+484,496
| +9% | +$4.9M |
|
14
TSMC
TSM
$1.94T
| $48.7M | 2.32% |
710,780
| – | – |
|
15
Alibaba
BABA
$276B
| $40.1M | 1.91% |
500,827
| – | – |
|
16
Mirum Pharmaceuticals
MIRM
$6.56B
| $35.4M | 1.69% |
1,684,193
-343,131
| -17% | -$8.26M |
|
|
VERV
17
DELISTED
Verve Therapeutics
VERV
| $31.3M | 1.49% |
911,111
-15,989
| -2% | -$510K |
|
18
BioMarin Pharmaceuticals
BMRN
$11.9B
| $26.9M | 1.28% |
317,500
| – | – |
|
|
FOLD
19
DELISTED
Amicus Therapeutics
FOLD
| $21.9M | 1.05% |
2,100,000
-535,000
| -20% | -$5.96M |
|
|
BPMC
20
DELISTED
Blueprint Medicines
BPMC
| $20.9M | 0.99% |
316,674
| – | – |
|
|
VECT
21
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
| $20M | 0.96% |
3,339,484
| – | – |
|
22
Alnylam Pharmaceuticals
ALNY
$38.3B
| $20M | 0.95% |
100,000
+15,200
| +18% | +$2.9M |
|
23
Vaxcyte
PCVX
$7.65B
| $19.8M | 0.94% |
823,705
| – | – |
|
24
Milestone Pharmaceuticals
MIST
$129M
| $18.4M | 0.88% |
2,000,000
-530,003
| -21% | -$4.02M |
|
|
UTRS
25
DELISTED
Minerva Surgical, Inc. Common Stock
UTRS
| $17.2M | 0.82% |
93,144
-9,301
| -9% | -$352K |
|
Similar funds
HCA
GX
MP
FLII
IC
CCA
WCM
IA
Novo Holdings A/S's Q3 2022 Portfolio in Review
As of Q3 2022, Novo Holdings A/S held 56 positions worth $2.1B, up 3.3% from $2.03B the previous quarter. Its ten largest holdings account for 65% of the portfolio.
Novo Holdings A/S withdrew a net $64.5M in Q3 2022, closing 4 positions and reducing 13 holdings. Its most notable exit was Morphic Holding, Inc. Common Stock, an estimated $12.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 52% of assets, down from 59% a quarter earlier, followed by Technology and Financials.
Against the trend, Novo Holdings A/S opened a new position in Seagen Inc. Common Stock worth $10.3M.
- Novo Holdings A/S's largest Q3 2022 buy was Seagen Inc. Common Stock: 75,000 shares worth $10.3M.
- Novo Holdings A/S added most to Cable One in Q3 2022, an estimated $43.9M increase.
- Novo Holdings A/S's biggest Q3 2022 reduction was Boston Scientific, cutting an estimated $70M.
- Novo Holdings A/S fully exited Morphic Holding, Inc. Common Stock in Q3 2022, selling an estimated $12.3M.
- Novo Holdings A/S's ten largest holdings make up 65% of its $2.1B portfolio in Q3 2022.
- Novo Holdings A/S opened 2 new positions and closed 4 in Q3 2022.
- Novo Holdings A/S's portfolio value rose 3.3% quarter-over-quarter to $2.1B.
Based on Novo Holdings A/S's 13F filing for Q3 2022, filed 14 Nov 2022.